Risuteganib

N/A

Report date: 2024/04/04 20:00:31
NME

Base Information

Drug NameRisuteganib
Drug Alias NameIntegrin Peptide TherapyLuminateALG-1001AM011AM-011(Allegro Ophthalmics)
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionIntegrin antagonists
TargetsIntegrin alpha-V/beta-5Integrin alpha-5/beta-1Integrin alpha2/beta1 +[5] 
Therapy Area/IndicationsDiabetic macular oedemaGeographic AtrophyMacular Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMexicoMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAllegro Ophthalmics Llc
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdAffaMed TherapeuticsAffamed Therapeutics Ltd
Inactive CompaniesAllegro Ophthalmics Llc
Active IndicationsMacular Degeneration
Inactive IndicationsDiabetic macular oedemaGeographic AtrophyDiabetic Retinopathy

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG